Quinn Opportunity Partners LLC Boosts Stock Position in Tilray Inc (NASDAQ:TLRY)

Quinn Opportunity Partners LLC lifted its holdings in shares of Tilray Inc (NASDAQ:TLRY - Free Report) by 108.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,618,080 shares of the company's stock after purchasing an additional 840,000 shares during the period. Quinn Opportunity Partners LLC owned 0.17% of Tilray worth $2,152,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Verdence Capital Advisors LLC purchased a new stake in Tilray in the 4th quarter worth about $29,000. Dudley Capital Management LLC bought a new position in Tilray during the 4th quarter worth approximately $29,000. Ameritas Advisory Services LLC bought a new stake in Tilray in the 4th quarter worth $32,000. Newman Dignan & Sheerar Inc. raised its holdings in shares of Tilray by 61.9% during the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock valued at $35,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Brooklyn FI LLC bought a new stake in shares of Tilray during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 9.35% of the company's stock.

Tilray Stock Up 7.9 %

Shares of TLRY stock traded up $0.04 on Wednesday, hitting $0.51. The stock had a trading volume of 17,287,327 shares, compared to its average volume of 29,374,216. The company has a quick ratio of 1.58, a current ratio of 2.54 and a debt-to-equity ratio of 0.10. The company has a market cap of $478.20 million, a PE ratio of -1.70 and a beta of 1.88. Tilray Inc has a one year low of $0.44 and a one year high of $2.52. The business has a 50 day moving average price of $0.70 and a 200 day moving average price of $1.15.

Tilray (NASDAQ:TLRY - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). The business had revenue of $185.78 million for the quarter, compared to analyst estimates of $213.38 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. Research analysts anticipate that Tilray Inc will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Piper Sandler lowered their target price on Tilray from $2.00 to $1.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.